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Objectives: Little is known about the performance of re-used pacemakers and implantable 
cardioverter defibrillators (ICDs) in Africa. We sought to compare the risk of infection and 
the rate of malfunction of re-used pacemakers and ICDs with new devices at Groote Schuur 
Hospital in Cape Town, South Africa.   
Methods: This was a retrospective case comparison study of performance of re-used 
pacemakers and ICDs in comparison with new devices at Groote Schuur hospital over a 10 
year period. The outcomes were incidence of device infection, device malfunction, early 
battery depletion, and device removal due to infection, malfunction, or early battery 
depletion.  
Results: Data for 126 devices implanted in 126 patients between 2003 and 2013 were 
analysed, of which 102 (81%) were pacemakers (51 re-used and 51 new) and 24 (19%) were 
ICDs (12 re-used and 12 new). There was no device infection, malfunction, early battery 
depletion or device removal in either the re-used or new pacemaker groups over the median 
follow up of 15.1 months (interquartile range (IQR), 1.3-36.24 months) for re-used 
pacemakers and 55.8 months (IQR, 20.3-77.8 months) for new pacemakers. In the ICD 
group, no device infection occurred over a median follow up of 35.9 months (IQR, 17.0-70.9 
months) for re-used ICDs and 45.7 months (IQR, 37.6-53.7 months) for new ICDs. One 
device delivered inappropriate shocks which resolved without intervention and no harm to the 
patient, this re-used ICD subsequently needed generator replacement 14months later. In both, 
the pacemaker and ICD groups, there were no procedure non related infections documented 
for the respective follow up periods. 
Conclusion: No significant differences were found in performance between re-used and new 






device removal for complications. Pacemaker and ICD reuse is feasible and safe and is a 























PART 1: LITERATURE REVIEW 
Background 
Pacemaker and implantable cardioverter defibrillator (ICD) implantation is an effective tool 
to treat bradyarrhythmias and life threatening tachyarrhythmias. The challenge with pacing 
and ICD use is the high cost of the devices. The high cost of pacemakers and ICDs has 
resulted in limited access of these life-saving interventions to deserving patients in 
developing countries.1 
Epidemiology 
Cardiovascular disease is the primary cause of mortality worldwide, accounting for 30% of 
all global deaths,1 of which more than 80% of these deaths occur in people living in 
underprivileged/low and middle-income countries (LMIC).1 LMICs are defined by the World 
Bank as countries that are generating a gross national income per capita that is lower than 
US$9200.1-3 Mortality attributable to cardiovascular disease is double the mortality rate of 
HIV/AIDS, malaria, and tuberculosis combined worldwide.4 There have been a declined in 
morbidity and mortality attributable to cardiovascular disease in recent decades as a result of 
improvements in technology and a greater emphasis on primary and secondary preventative 
strategies in the developed world.1, 5 It is unfortunate that in LMICs this dramatic 
improvement in disease burden has not been witnessed.1, 6   
 In LMICs, secondary treatments are often limited because of the lack of skilled healthcare 
providers and more importantly, financial burden where by the patients are unable to afford 
costly medical procedures.4  
This disparity in medical health care is evident in the field of cardiac electrophysiology, 






This specialty is either severely underdeveloped or entirely non-existent in many LMICs.7 
This results in suffering and death of patients with symptomatic bradycardia who cannot 
afford these devices or have no access to appropriate services (personal correspondence, 
University of Philippines-Philippines General Hospital, 15 November 2008).1 
 In South Africa, public health care services are tax funded and provide service at all levels of 
the health system.8-11 People using public health care services have to pay a fee related to 
their income except for pregnant women and children under the age of six years.11 Because of 
the diversion of funds from tertiary health care facilities to the primary care level, budgetary 
constraints to provision of tertiary services like cardiac surgery, cardiology and other 
expensive services have been witnessed.11    
Review  
 Scott Millar et al8 conducted a survey of cardiac pacing in South Africa in 1998 and 
identified a total of 1,643 new pacemakers implanted by 112 doctors working at 31 
institutions (9 public centres and 22 private centres).8 They reported an increase of 25.8% 
annual implant rate from 31 per million population in 1995 to 39 per million population in 
1998 with 31.7% primary pacemaker implants in public sector in 1998 compared to 37 % in 
1995.8 
There was a huge difference between public and private sector practice with regards to 
indications of pacemaker implantation and type of pacemaker implanted due mainly to 
affordability, with the public sector being mostly where the financial burden was being 
observed.8 In the public sector, atrioventricular (AV) block was the main indication for 
pacing in 75.3% of cases as opposed to 45.3% in the private sector,8 whereas sinus node 







Single-chamber pacemakers were the most utilised devices in the public sector and accounted 
for 49.5% of public sector implants as opposed to only 9.6% in private sector.8 On the other 
hand reverse was true concerning dual-chamber implants with 12.1% implants in the public 
sector versus 42.3% in the private sector being dual chamber.8 This difference as alluded 
above was because of the difference in budgets between the two sectors. Dual-chamber 
devices are more expensive compared to single chamber pacemakers, and sinus node 
dysfunction is predominantly left untreated provided is asymptomatic in the public sector. 
 
Because of the difference in socio-economic status between racial groups in South Africa, 
there was an observed difference in implantation rates between them.8 There were 232 per 
million implants in the white population as opposed to 8.8 per million implants in the black 
population.8 Regional differences also exist due to uneven distribution and lack of trained and 
skilled implanters in some parts of the country.8 The Western Cape had 89.3 per million 
population implants as compared to 10.8 per million population in the four provinces within 
the country without pacemaker implanters.8 
   
Despite the growth of implants from 1995 to 1998, the pacemaker implantation rate is still 
lower than the developed world. The South African implant rate remains low at 39 per 
million population compared to the median implant rate of 283 per million in Europe.8 This 
discrepancy is attributed to socio-economic factors that play a prominent role in the uneven 








Mayosi et al10 conducted a survey in the sub-Saharan region north of South Africa to 
determine the distribution of implanters and changing trends in pacing practice during 1995.  
Cameroon, Ghana, Ivory Coast, Kenya, Mauritius, Namibia, Nigeria, Senegal, Seychelles and 
Zimbabwe were the only countries in sub-Saharan Africa identified to have permanent 
pacemaker implanting centres.10 This survey showed an increase in the number of countries 
with cardiac pacing centres in the sub-Saharan region north of South Africa (from 3 countries 
in 1981 to 10 countries in 1995).10   
 
Mayosi et al11 in 2002 tried to ascertain the utilization of ICDs in Africa through an electronic 
mail survey of cardiologists working in West, Central and East Africa and demonstrated that 
South Africa was the only country in Africa in which ICD implantation was being practised.  
This survey showed yet another increase in primary pacemaker implantation rate from 39 per 
million population in 1998 to 41 per million population in 2001, whilst the ICD implantation 
rate were 0.8 per million population.11 The majority of the ICDs implanted in 2001 were 
privately funded with only 3 of the 35 implants that were implanted in a public hospital 
(Groote Schuur hospital) after a direct appeal to the authorities to fund the devices.11 
 
 Severe financial constraints prevented implantation of these devices by public hospitals, 
even those with the necessary expertise.11 Marked regional and racial differences in 
implantation rates were identified, reflecting large socio-economic disparities between 
different regions and groups.8-9 The rural black South Africans were the one severely affected 








Mond et al7 in the 2005 World Survey of Cardiac Pacing and Cardioverter-Defibrillators 
demonstrated that the rates of new pacemaker implants in the United States of America 
(USA), Canada and Western Europe were over 380 per million population with USA having 
the highest rates at 752 per million populations compared to the underprivileged countries 
with 54 per million population in South Africa, 22 per million population in Thailand, 14 per 
million population in Peru and 4 per million population in Bangladesh.7 ICD implantation 
showed similar results with USA having 401 per million population new implants as opposed 
to South Africa with 2 per million population, 3 per million population in Thailand, <1 per 
million population in Peru and Bangladesh.7   
 
Mond et al12 in the 2009 Worldwide Cardiac Pacing and ICD survey (Table 1 and 2) 
demonstrated that all countries participated in that survey showed an increase in the numbers 
of implant over the 4 year period from previous survey in 2005. This was the largest pacing 
and ICD survey ever performed encompasses more than 80% of all the pacemakers and ICDs 
implanted worldwide, with about sixty one countries contributed to the survey: 25 European 
countries, 20 Asian Pacific countries, 7 Middle East and African countries and 9 states in the 
USA.12 
 
This survey included about 1,002,664 pacemakers of which 737,840 were new implants and 
264,824 were replacements.12 The USA had the largest number of pacemaker implants of 
225,567 while Germany had the highest number of new pacemaker implants (927 per million 








That survey also involved 328,027 ICDs of which 222,407 were new ICD implants while 
105,620 were generator replacements.12 All countries that participated showed a significant 
increase in the use of ICDs with the USA having the highest number of implants of 133,262 
which corresponded to 434 implants per million population (Table 2).12 
 
As Scott Millar et al8 has shown in the South African survey in 1998 that atrioventricular 
block and sinus node dysfunction were the major indications for pacemaker implantation in 
the public sector and private sector respectively. This survey demonstrated the same result. 
Single chamber pacemakers were predominantly being utilised in the developing countries.12 
 Dual chamber implants showed an increase in comparison to 2005 survey in all countries 
which were surveyed.12 South Africa and Sudan were the only African countries participated 
in the survey.12 
 
The high cost of these devices is attributed to the observed disparity between countries as 
shown in the table 1 and 2. As the cost of these devices differs with type or function of the 
devices, the pacemaker pulse generator at its most basic form costs around $2.500-3.000 and 
leads cost around $800-1.000, whereas ICD generator costs range from $20.000-40.000 and 
leads cost over $10.000.13 Clearly underprivileged countries with meagre health care budgets 
will not afford these devices for everyone in need who cannot buy their own device, hence 
sterilization and reuse of these devices deserves consideration. 
 
Pacemaker implantation is a lifesaving intervention for patients suffering from 
bradyarrhythmias.14 Death from untreated atrioventricular block is not only due to heart 
failure secondary to low cardiac output, but also to sudden cardiac death caused by prolonged 






Patients with acquired complete atrioventricular block have a very poor prognosis with 1-year 
survival rates only between 50-70% compared to sex and age-matched controls, after 
atrioventricular block related syncope.16-22 Although formal randomised controlled trials of 
pacing atrioventricular block have not be performed, it is clear from observational studies that 
pacing prevents recurrence of syncope and improves survival.15  
 
Due to high cost of these devices, patients in underprivileged countries where there is no full 
medical coverage in place to buy the devices suffer and die because they cannot afford these 
devices. It was thought that donation of new devices by various charities to these countries 
would be the solution to this problem but the demand of these devices exceeds what these 
charities can offer.14   
 
In order to overcome the unmet demand and address the disparity between countries, 
cadaveric donation of these devices is thought to be an option for these patients in these 
countries.14, 23-32 Reuse of cardiac pacemakers has been practiced since the early 1970’s.33 It 
remains an option for those countries who cannot afford new devices.14, 23-32 These devices 
are carefully selected and sterilised for reuse. 14, 23-32 At the moment there are no standardized 
protocols for sterilization of these devices, most centres follow chemical sterilization with 
biozyme and/ or orthozyme, followed by gas sterilization with ethylene oxide to meet the 
standards of that particular hospital’s sterilization unit.  
 
Pacemaker reuse is being practiced in many countries like India, Romania, Philippines, 
Canada, Australia, Italy, Sweden, Holland, Norway, Brazil, Hungary, Finland and Israel.23 To 







This practice has raised concerns of device infection and malfunction.28-29, 35-40 There are 
several factors associated with a greater risk of cardiovascular implantable electronic device 
infection (1) immunosuppression; (2) oral anticoagulation use; (3) patient coexisting 
illnesses; (4) peri-procedural factors, including the failure to administer peri-operative 
antibiotics; (5) device revision/replacement; (6) amount of indwelling hardware; (7) operator 
experience.41 In recent years studies have been conducted to address these concerns about this 
practice. 14, 23-32 
 
Staphylococcus aureus is the most common culprit isolated in the vast majority of cases, and 
to a lesser extent coagulase-negative staphylococci (staphylococcus epidermis).42-51 
Antibiotic use at the time of implantation has significantly reduced the incidence of implant 
associated infections. Da Costa et al, in a meta-analysis of seven randomised-controlled trials, 
studying the effectiveness of systemic prophylactic antibiotics in reducing pacemaker-related 
infections, demonstrated that antibiotic use at the time of implantation significantly reduced 
the incidence of implant associated infections (combined odds ratio 0.256, p=0.046).42 Klug 
et al demonstrated a significant reduction in infections related to pacemakers (N=5866) and 
cardioverter-defibrillators (n=453) implantations, in a study of 6319 implants with systemic 
prophylactic antibiotics at implantation (odds ratio 0.4).43 
 
Oliveira et al in a study of 649 conservative patients randomised to either 1g intravenous 
cefazolin or placebo showed that prophylactic antibiotic use significantly reduced the 
incidence of infection (relative risk 0.19, p=0.016).50 There are no guidelines on systemic 
prophylactic antibiotic use during pacemaker implantation, and the decision on whether to 
use antibiotics is usually at the discretion of the operator.51 Due to the lack of studies 






Different centres use different antibiotic regimens.51 It is difficult to evaluate a superior 
regimen, antibiotic that covers staphylococcus aureus as it is the main culprit is 
recommended.51 Narrow spectrum antibiotics with staphylococci species coverage are 
preferred because of the risk of antibiotic associated diarrhoeas associated with broad 
spectrum antibiotics.  
 
Flucloxacillin alone appears to be the most common regimen, intra-pocket gentamycin is also 
used in some centres.51 Both regimes rarely cause clostridium difficile associated 
diarrhoea.52-54 Most expert advocate cefazolin for prophylaxis.41 But single dose cefazolin is 
known to cause clostridium difficile associated diarrhoea.55-56 There are no randomised-
controlled trials studying the effectiveness of prophylactic intra-pocket gentamycin in 
pacemaker implantation, this practice still needs further studies.51  
 
There is a wide variation in the duration of antibiotic use post implantation, Dwivedi et al 
demonstrated that short course is just as effective as a longer course in preventing device 
infections,44 but this still needs to be further studied. Preoperative antiseptic preparation of 
the skin of the surgical site and intra-procedural compulsive attention to sterile technique is 
mandatory in catheterization laboratories.41 Haematoma formation prevention is mandatory 
post operatively.41  
Professional associations have shown support of this practice. The National Association for 
Sport and Physical Education in 1985 supported the practice and considered it as a reasonably 
safe practice.57 The American College of Cardiology/American Heart Association/National 
Association for Sport and Physical Education later acknowledged in 2002 that pacemaker 






 Currently, Food and Drug administration (FDA) regulations prohibit device reutilization as it 
is regulated as a class III device that is not to undergo re-sterilization with subsequent 
distribution.59 Shipping of these devices unprocessed (as a hazardous material with no 
intention of human use) to the recipient country or institution, leaving the responsibility of 
sterilization and testing to the recipient institution was one of the proposed methods to 
address regulatory concerns but this placed a heavy burden on the underprivileged country.60 
Another approach is to file for FDA approval for potential exportation of re-sterilized devices 
only to those in need in undeserved nations.61-62  
At present, Project My Heart-Your-Heart (PMHYH) is working with the FDA in order to 
provide a legal framework in the form of an investigational device exemption for those 
interested in providing this valuable resource to those in underserved nations.60 This practice 
seems to be an answer to those in need but cannot afford new device. Device infection is the 
most feared complication of this practice,47, 63-64 but there appears to be no significant 
difference in infection or mortality rates between reused and new device implantation.24, 64-66 
Linde et al24 reported a two year Swedish experience of pacemaker reuse. They conducted a 
retrospective case-control study of 100 consecutive patients who received re-used 
pacemakers either as a primary implant or replacement.24 The patients who received re-used 
pacemakers (i.e., re-used pacemaker group) were matched by date of implantation and pacing 
mode (e.g., AAI, VVI, DDD) to 100 patients that received new pacemakers (i.e., new 
pacemaker group) to investigate the safety of re-use of pacemakers.24 These patients were 
followed up over 32±11 months (means± standard deviation) for complications (e.g. 
pacemaker infections, pacemaker malfunction and early pacemaker replacement due to early 
battery depletion). The re-used pacemaker group was significantly older than the new 






Results revealed a 3% complication rate in re-used pacemaker group versus 7% in the new 
pacemaker group (Table 3).24 Eight of the complications that occurred were from primary 
implants (1=re-used pacemaker and 7=new pacemakers) and the rest (two) from replacements 
(2=re-used pacemakers).24 The new pacemaker group had slightly higher infections as 
compared to the re-used pacemaker group.24 One of the nine infections occurred before the 
era of routine intravenous antibiotics prophylaxis before pacemaker implantation.24 There 
were no pacemaker generator replacements due to early battery depletion during the 32±11 
months follow up.24 
 
Panja et al25 reported an Indian experience in a study of 642 patients with re-used pacemakers 
and the same number of new pacemakers looking to investigate infection rates between the 
two groups. 522 pacemakers in the re-used pacemaker group were pacemakers that were 
taken out of the same patient for whatever reason either infected or erosion or pre erosion, 
120 were taken from cadaveric donation.25 These pacemakers were sterilized and 522 were 
implanted back to the patients they were taken out from on the opposite side from the original 
site and 120 were implanted to patients who never had a pacemaker before.25  
 
Their results showed that pacemakers reuse in the same patient had higher infection rate of 
11.8% compared to cadaveric donated ones (5.1%) or new pacemaker implants (5.3%) over a 
follow up period of 7.5±5.6 years.25 This higher infection rate in the same patient implant was 
attributed to lymphatic or haematogenous spread from the previous infected pocket rather 






Rosengarten et al26 reported a Canadian experience in a prospective trial of new versus 
refurbished cardiac pacemakers. They implanted 70 pacemakers of which 52 (75%) were new 
and 18 (25%) were refurbished. The refurbished pacemakers were implanted in older patients 
with a mean± standard deviation age of 77±8 versus 69±13 years (P< 0.02).26  
The rate of pacemaker related complications were the same in both groups over a follow-up 
period of 36 months, with 12 (23%) complications in the new pacemaker group and 4 (22%) 
complications in the refurbished pacemaker group.26 
 
There were no major pacemaker related complications, early pacemaker battery depletions or 
pacemaker related deaths and this practice of refurbished pacemakers was shown to be cost 
effective and saved $33,000.26 After three years the cumulative probability of survival in the 
new group was higher (P = 0.08).26 New and refurbished pacemakers were similar with 
respect to pacemaker related survival and complications.26 Refurbished pacemakers effect a 
major reduction in pacemaker costs while maintaining health care standards.26  
Kantharia et al29 found no significant complications in an Indian study cohort of 53 patients 
who received cadaveric donated sterilized pacemakers over a mean follow up of 661 days. 
 
Catanchin et al47 conducted an Australian retrospective pacemaker and ICD infection 
analysis: of 10 years of experience between 1994-2004 and reported an infection rate of 
1.6%. Second or subsequent procedures carried a greater infection risk and mortality rate of 
2.6% over mean follow up of 29.3 months.47 
 
 Pavri et al67 reported an Indian experience of reuse of sterilized ICDs in a single centre 






of the re-implanted devices delivered life-saving shocks or antitachycardia pacing to the 
recipient over a mean follow-up of 825 days. 
 
Baman et al23 conducted a meta-analysis of studies published looking at outcomes of 
pacemaker reuse from 1970 to 2010 aiming to assess safety of pacemaker reuse. They 
included about 18 studies with total number of 2270 patients.23 The primary outcome of this 
meta-analysis was device infection or erosion with device malfunction as secondary end 
point.23They reported an infection rate of 1.97% (1.15%- 3%) associated with pacemaker 
reuse and device malfunction rate of 0.68% (0.27%- 1.28%), but there was no statistical 
significant difference in infection rates between new and re-used devices.23 Device 
malfunction was much higher for pacemaker reuse compared to new pacemakers with P=0.02 
that is statistical significant.23   
 
Limitations of this meta-analysis should be taken into account when interpreting these results, 
which are as follows: (1) of the 18 studies analysed, only 5 of them had direct comparison of 
reuse and new devices;23 (2) three of the studies included were published in an abstract 
form;23 (3) none of the included studies were randomised controlled trials;23 (4) the infection 
was not sub-classified into type and time of occurrence.14 Regarding higher malfunction, 
device screw issues either during explantation or implantation of these device contributed to 
the difference in malfunction between the two groups, careful selection and testing of these 
devices prior to sterilization and implantation seem to have decrease the difference.14 
 
Nava et al14 conducted an ambispective noninferiority study to address the issue of efficacy 
and safety of pacemaker reuse in a study of 603 (307 in study group and 296 controls) 






pacemaker reuse. From 2000 to 2005 the study was retrospective and from year 2006 to 2010 
it was prospective.14 They assessed three major outcomes as a combined end point (device 
infection, device malfunction or unexpected battery depletion) over a follow up period of 
4.10 years for the study group and 4.16 from controls.14  
 
 They found no statistically significant difference in infection rate and unexpected battery 
depletion between the two groups, and one device was found to be malfunctioning in the 
study group and no malfunction reported in controls.14 The malfunctioning of that device was 
due to a faulty screw. This problem was eliminated after a policy of careful fault inspection 
and testing prior to sterilization was introduced.14  
 
Conclusion  
From the above literature review, pacemaker and ICD reuse compared with new devices 
seem to have no significant difference in respect to device infection but there may be higher 
rate of device malfunction associated with device reuse.  Due to the absence of randomised 
controlled trials in this subject of pacemaker and ICD reuse, the safety and effectiveness of 
pacemaker and ICD reuse remains uncertain. To the best of my knowledge, no studies of the 
performance and safety of re-used pacemakers and ICDs have been conducted in Africa. This 
has prompted us to review and report our experience in Groote Schuur Hospital, Cape Town, 
South Africa with regard to the performance of re-used pacemaker and ICDs in comparison 










Table 1: Cardiac Pacing 2009 compared to 200512 
 Number of  New implants 
 Population             centres                 New implants Per Million centre 
Country                 (million)            (2005 survey)      (2005 survey) (2005 survey) 
Europe 
   German 82 986                    ∼76.046 927 
   France     62  550 (575)           ∼48.487 (44.915) 782 (738) 
   UK                                62 211 (191)              32.135 (26.930) 518 (447) 
Asia Pacific 
   Australia              22    111 (123)               12.523 (11.850)     565 (590) 
   China              1.300                 783 (417)         40.728 (16.595)       31 (13) 
   India              1.200                 738 (417)         20.000 (12.000) 17 (7) 
Africa/Middle East 
   South Africa 49       (47)               2.939 (2.515) 60 (54) 
   Sudan   39 4 180 5 
   Iran    72  54 (41)                3.373 (2.529)  47 (37) 
America 
   USA   307                  3.400                   232.567 (223.425)     767 (752) 
   Argentina 40       600                      11.478 (10.876)         287 (294) 
   Brazil    184  317 (252)             24.966 (19.071)         136 (103) 
 
































Table 2: Implantable Cardioverter Defibrillators 2009 compared to 200512  
 
                                                                                New implants 
                                    New implants                     Per Million Population 
Country                  (2005 survey) (2005 survey) 
Europe 
   German ∼23.752                           290 
   France              ∼6.720                              108 
   UK                                ∼5.990 (2.835)                              97 (47) 
Asia Pacific 
   Australia              3.555 (2.864)                               160 (142) 
   China              1.316 (186)        1 (<1) 
   India              1.100 (415)        1 (<1) 
Africa/Middle East 
   South Africa 308 (105)                          6 (2) 
   Sudan   2                                                     < 1 
   Iran    1,260 (314)                           18 (5) 
America 
   USA   133.262 (119.121)                     434 (401) 
   Argentina 2.250 (672)                      56 (18) 
   Brazil    2.825 (1.413)                                   15 (8) 
 
(2005 survey) = comparison with 2005 survey; UK= United Kingdom; USA= United States of America 
 
Table 324 








Pacemaker Infection Malfunction Total 
New pacemaker group 7 0 7 
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Objectives: Little is known about the performance of re-used pacemakers and implantable 
cardioverter defibrillators (ICDs) in Africa. We sought to compare the risk of infection and 
the rate of malfunction of re-used pacemakers and ICDs with new devices at Groote Schuur 
Hospital in Cape Town, South Africa.   
Methods: This was a retrospective case comparison study of performance of re-used 
pacemakers and ICDs in comparison with new devices at Groote Schuur hospital over a 10 
year period. The outcomes were incidence of device infection, device malfunction, early 
battery depletion, and device removal due to infection, malfunction, or early battery 
depletion.  
Results: Data for 126 devices implanted in 126 patients between 2003 and 2013 were 
analysed, of which 102 (81%) were pacemakers (51 re-used and 51 new) and 24 (19%) were 
ICDs (12 re-used and 12 new). There was no device infection, malfunction, early battery 
depletion or device removal in either the re-used or new pacemaker groups over the median 
follow up of 15.1 months [interquartile range (IQR), 1.3-36.24 months] for re-used 
pacemakers and 55.8 months (IQR, 20.3-77.8 months) for new pacemakers. In the ICD 
group, no device infection occurred over a median follow up of 35.9 months (IQR, 17.0-70.9 
months) for re-used ICDs and 45.7 months (IQR, 37.6-53.7 months) for new ICDs. One 
device delivered inappropriate shocks which resolved without intervention and no harm to the 
patient, this re-used ICD subsequently needed generator replacement 14months later. In both, 
the pacemaker and ICD groups, there were no procedure non related infections documented 
for the respective follow up periods. 
Conclusion: No significant differences were found in performance between re-used and new 
pacemakers and ICDs with respect to infection rates, device malfunction, battery life and 
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device removal for complications. Pacemaker and ICD reuse is feasible and safe and is a 
viable option for patients with bradyarrhythmias and tachyarrthythmias.  
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Introduction 
 Pacemaker implantation is an effective tool to treat bradyarrhythmias, and implantable 
cardioverter defibrillators (ICD) reduce mortality in patients at high risk of sudden death.1 
The challenge with pacemakers and ICDs is the high cost of these devices. The pacemaker 
generator in its most basic form costs US$ 2.500-3.000 and leads cost US$800-1.000.2 An 
ICD generator costs US$ 20.000-40.000 and leads cost over US$10.000.2 The high cost of 
pacemakers and ICDs has resulted in limited access of deserving patients in poor countries of 
these life-saving interventions.3-5 
Mond et al.6 demonstrated an increase in pacemaker and ICD implantation rates in all 
countries that participated in the World Survey of Cardiac Pacing in 2009. Despite this 
increase in implantation rates, there was a huge difference in the number of implants between 
the developed and underprivileged countries, with more implants in the developed world.6
This disparity was explained mainly by the high cost of these devices.6
Reuse of cardiac pacemakers has been practiced since the early 1970’s.7 The major concern 
with this practice is the risk of device infection and malfunction.8-11 Device infection is the 
most feared complication of cardiac device reuse and is thought to be associated with case 
fatality rate between 2.6 to 18%.12-14 However, some studies from America, Europe and Asia  
that examined the performance of re-used pacemakers and ICDs have shown no significant 
difference in infection or mortality rates between patients who received re-used and new 
devices.14-22
The aim of this study was to investigate the performance of re-used pacemakers and ICDs at 
Groote Schuur Hospital, Cape Town, South Africa. 
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Methods 
This was a retrospective case comparison study of performance of re-used versus new 
pacemakers and ICDs at Groote Schuur Hospital, Cape Town, South Africa. We included 
consecutive devices that were implanted between 01 January 2003 and 01 January 2013. As 
shown in Fig. 1, there were 1721 devices implanted during that time, of which 1587 (92.2%) 
were pacemakers and 134 (7.8%) were ICDs. Of the 1587 pacemakers, 1257 (79.2%) were 
new implants and 330 (20.8%) were generator replacements. Of the 134 ICDs, 114 (85.1%) 
were new implants and 20 (14.9%) were generator replacements.  
There were 54 (3.4%) re-used pacemakers and 12 (9%) re-used ICDs implanted during this 
period, with a total number of 66 (3.8%) re-used devices implanted as shown in Fig. 1.  
Patients with re-used devices (i.e., cases) were then matched by age, gender and date of 
implantation on 1:1 basis to patients with new devices (i.e., controls). In the pacemaker 
group, cases and controls were matched to the same month of implantation, and for the ICD 
group, to the same year of implantation.  
Criteria for reuse 
Devices for reuse were obtained from cadaveric donors. They were inspected for external 
damage and tested for remaining battery life. Devices with less than two years of battery life 
remaining and/or with external evidence of damage were not re-used. Only devices with two 
or more years of battery life remaining with no evidence of external damage were eligible for 
reuse.  
The eligible devices were sterilised by immersion in biozyme for 24 hours, followed by 
peroxide for further 24 hours and then orthozyme for another 24 hours. After the three days 






subjected to gas sterilization. In the gas sterilization unit, they were put in a machine with 
ethylene oxide for 4.5 hours and irradiated for two cycles of 30 minutes three days apart. 
After device sterilisation, all devices were checked by a cardiac technologist in the 
department for any visual defects, device longevity and were tested to determine if they were 
functioning appropriately for reuse. Device manufacturer’s personnel were not involved in 
this process.  A cardiac technologist or cardiology registrar in training was present at every 
implant procedure. Standard measurements were obtained during the implant after lead 
positioning (capture thresholds, battery life, sensitivities, and lead impedances) and again 
prior to discharge. Defibrillation testing was performed in all ICDs post implantation and all 
were functioning well with appropriate thresholds.  
Re-used pacemakers were implanted mainly in elderly patients with multiple co-morbidities 
such as advanced cancer (on treatment or in remission), cerebro-vascular accident (CVA), 
advanced chronic obstructive pulmonary disease (COPD), dementia and/or a poor baseline 
level of functioning (mostly bed bound) who were expected to have a significantly reduced 
life expectancy. Re-used ICDs were implanted in patients who met the secondary prevention 
criteria for sudden death and co-morbidity was not a factor in determining who received a re-
used ICD. The inherent difference between patients who received re-used pacemakers 
compared to those who had new pacemakers, led us not to compare the outcome of patients 
in the two groups. The units of analysis were devices themselves. Every patient provided a 





Implantation Procedure and Follow-up 
Devices were implanted by a cardiac electrophysiologist, cardiologist or a cardiology senior 
registrar. Prior to implantation, patients received 1gram of intravenous infusion of cefazolin 
as prophylaxis. Patients were discharged from hospital the following day provided there were 
no complications and were followed up in the Pacemaker Clinic at 3 months and yearly 
thereafter. Patients with ICDs were followed up more frequently at 3-4 monthly intervals
Outcomes 
The outcomes of interest were procedure-related infection, device malfunction, early battery 
depletion, and device explantation for infection, malfunction and/or battery depletion.  
The definitions of the outcomes are as follows:
Procedure-related infection: 
Infections were classified into four types:23
(1) Right sided endocarditis with lead involvement; (2) Sepsis with evidence of
involvement of the lead and implantation pocket; (3) Involvement of pacemaker
implantation pocket; and (4) Involvement of lead or generator.
Infections were considered early if the onset of illness was within the first month of 
implantation, and late if the onset of illness was after the first month to a year after 
implantation.23 Infections that occurred after a year of implantation were considered not to be 
related to the procedure.23 It is thought that procedure related infection manifests within the 







Device malfunction  
Device malfunction was defined as failure of the device to accomplish a desired role, e.g., in 
case of an ICD, not able to sense ventricular tachycardia/fibrillation and deliver appropriate 
treatment. In case of a pacemaker, device malfunction was defined as inability to sense or 
pace when required. 
Early battery depletion 
Early battery depletion was defined as battery depletion within 6 years of implantation for 
new devices. For re-used devices, early battery depletion was defined as battery depletion 
within 1-2 years of implantation for those with 2-4 years battery life remaining, and within 2 
years of implantation for those with 4 years or more battery life remaining at the time of 
implantation, provided this depletion was not explained by high pacing outputs or abnormal 
electrode impedance.  
Device explantation for infection, malfunction and/or battery depletion 
Removal of the pacemaker or ICD for infection, malfunction or early battery depletion 
Data extraction 
The cardiac Clinic Electrophysiology Database was used to identify the cases with re-used 
devices and controls with new devices. Data were extracted from clinical notes in the Cardiac 
Clinic and additional information from pacemaker cards in the Cardiac Catheterization 
Laboratory and clinical records. Patient status was taken from clinical notes, the hospital 









Categorical data were summarized as proportions and continuous data as means and standard 
deviations or medians and inter-quartile range. Categorical data were compared using the 2 
test, and continuous data using t-test or Mann-Whitney test. All tests were two-sided and a p-
value of <0.05 was considered significant. IBM SPSS (version 19, IBM Corp., NY, USA) 
was used to perform the analysis. 
Results 
Three patients with re-used pacemakers were excluded from the analysis because of missing 
records. Data for 126 devices inserted in 126 patients between 2003 and 2013 were analysed, 
of which 102 (81%) were pacemakers (51 re-used and 51 new) and 24 (19%) were ICDs (12 
re-used and 12 new). For the pacemaker group the median follow up for patients with re-used 
devices (i.e., cases) was 15.1 months [interquartile range (IQR), 1.3-36.24 months] and for 
those with new devices (i.e., controls) was 55.8 months (IQR, 20.3-77.8 months).  
In the ICD group the median follow up for patients with re-used devices (i.e., cases) was 35.9 
months (IQR, 17.0-70.9 months) and those with new devices (i.e., controls) was 45.7 months 
(IQR, 37.6-53.7 months).  
 Baseline characteristics of patients who received pacemakers are shown in Table 1 and 
pacemaker parameters are shown in Table 2. As expected re-used pacemaker cases had more 
significant co-morbidities compared to pacemaker controls. They were more likely to have 
advanced cancer, cerebro-vascular accident (CVA), advanced COPD and dementia with a 
poor baseline level of functioning mainly bed bound (due to CVA, dementia, atherosclerotic 






There were no differences between the two groups with respect to pacemaker parameters as 
shown in Table 2.  
Baseline characteristics of patients who received ICDs are shown in Table 3 and there were 
no significant differences between the two groups. ICD parameters are shown in Table 4 and 
there were no significant differences between the two groups. 
The pacemaker group was analysed separately from the ICD group. In the pacemaker group 
there were no device infections, pacemaker malfunction, early battery depletion or 
explantation of pacemaker due to infection, malfunction and early battery depletion identified 
after a median follow up of 15.1 months (IQR, 1.3-36.24 months) for cases and 55.8 months 
(IQR, 20.3-77.8 months) for controls. There were no procedure non related infections 
documented for this follow up period.  
For pacemaker cases, 10 (19.6%) patients were followed up for 5years and more, 18 (35.3%) 
for 1-5 years and 23 (45.1%) for less than a year. For pacemaker controls 23 (45.1%) patients 
were followed up for 5 years and more, 21 (41.2%) for 1-5 years and 7 (13.7%) for less than 
a year.  
In the ICD group, there was one device in the re-used device group that delivered 
inappropriate shocks (i.e., inappropriate delivery of shocks for supraventricular tachycardia), 
during the early stages of implantation but this resolved without any intervention.  This 
device subsequently needed generator replacement after 14 months from implantation. There 
were no device infections identified after a median follow up of 35.9 months (IQR, 17.0-70.9 
months) for cases and 45.7 months (IQR, 37.6-53.7 months) for controls. There were no 






For ICD cases, 5 (41.7%) patients were followed up for 5years and more and 7 (58.3%) for 1-
5 years and for ICD controls 7 (58.3%) were followed up for 5 years or more, 5 (41.7%) for 
1-5 years.  In both groups (pacemaker and ICD) there were no devices explanted for infection 
or malfunctioning during the follow up period.  
  
In the re-used pacemaker group, 26 (51%) patients attended follow up at 3 months, whereas 
25 (49%) did not attend. Of those who did not attend, 11 (44%) were dead, 9 (36%) were 
alive and 5 (20%) were lost to follow up (Fig. 2). Of those who died 8 (72.7%) were 
documented to have died from natural causes, 1 (9.1%) from cancer and 2 (18.2%) from non-
pacemaker related sepsis of which one died within 24hours of implantation and the other one 
after two months of implantation. The patient who died within 24 hours of device 
implantation was admitted with a methicillin resistant Staphylococcus aureus (MRSA) 
endocarditis prior to pacemaker implantation. 
 
In the new pacemaker group, 43 (84.3%) patients attended follow up at 3 months, whereas 8 
(15.7%) did not attend follow up. Of those who did not attend, 1 (12.5%) was dead and 7 
(87.5) were alive (Fig. 2). The patient who died was an 87 year old man who passed away at 
home two days after pacemaker implantation from natural causes.  
 
At 1year follow up, 19 (37.3%) patients attended follow up, whereas 32 (62.7%) did not 
attend follow up in the re-used pacemaker group. Of those who did not attend follow up, 15 
(46.9%) were dead, 9 (28.1%) were alive and 8 (25%) were lost to follow up (Fig. 2). All 






For new pacemaker group, 38 (74.5%) patients attended follow up while 13 (25.5%) patients 
did not attend follow up at one year. Of those who did not attend follow up, 3 (23.1%) were 
dead, 7 (53.8%) were alive and 3 (23.1%) were lost to follow up (Fig. 2). All deaths were due 
to natural causes. 
In the ICD group, there was 100% attendance for both cases and controls at 3 months follow 
up. At 1year follow up there was 100% attendance for cases compared to 91.7% for controls 
with 1 (8.3%) patient absent but this patient was discharged from Groote Schuur Hospital at 
3months of follow up to be followed in Port Elizabeth and is still alive (Fig 2). 
Discussion 
This study shows that the reuse of pacemakers and ICDs is feasible and safe at Groote Schuur 
Hospital in Cape Town, South Africa. There was no difference in the incidence of device 
infection, malfunction, battery failure or explantation due to complications between re-used 
and new devices. Indeed, device implantation was associated with no complications in this 
series.  
To the best of our knowledge this is the second study ever published of the outcomes of re-
used implantable cardioverter defibrillators (ICDs).25 In our study, there were no device 
infections and/ or device explanted for malfunction identified. There were no patients that 
were lost to follow up in this group.  
Linde et al.22 in a retrospective case control study found no significant difference in device 
infection, although paradoxically more infections were found in the new pacemaker group 
(7%) than in reused pacemaker group (2%). Kantharia et al.26 found no significant 
complications in an Indian study cohort of 53 patients who received cadaveric donated 
resterilized pacemakers over a mean follow up of 661 days.  
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Panja et al.27 found no difference in infection rates between new pacemaker group and 
cadaver donated re-used pacemakers, but higher rates of infection on infected re-sterilized 
devices that were implanted on the same patient that were taken out from and implanted on 
the opposite side. They attributed this higher infection rates to haematogenous or lymphatic 
spread from previous infected pocket.27 Rosengarten et al.28 also found no significant 
difference in major pacemaker related complications and reported that reuse of devices is cost 
effective.    
Pavri et al.25 in a retrospective single centre cohort study of re-sterilized ICDs found no 
device related infections and 60.4% re-used ICDs delivered life-saving shocks. Baman et al.29 
in a meta-analysis of 18 studies found no significant difference in infection rates between 
new device group and re-used device group but much higher device malfunction associated 
with re-used devices compared to new devices. This malfunction was attributed to 
abnormality in set screws.29 In a recent study, Nava et al.23 found no significant difference in 
infection rates between re-used and new devices, although more infections were found in the 
new device group. They also found more device malfunction in the re-use device group 
which was similar to the previous quoted studies and also the fault was attributed to faulty 
pacemaker screws.23 
 Device infection is thought to be associated with mortality rate between 2.6 to 18%.12-14 
There are several factors associated with a greater risk of cardiovascular implantable 
electronic device infection (1) immunosuppression; (2) oral anticoagulation use; (3) patient 
coexisting illnesses; (4) peri-procedural factors, including the failure to administer peri-
operative antibiotics; (5) device revision/replacement; (6) amount of indwelling hardware; (7) 
operator experience.30 However studies that examined this issue showed no significant 






 In our study we did not compare mortality rates between the two groups because of the 
selection bias of those who received re-used pacemaker.  
 
Although re-used pacemaker patients had more co-morbidities and were expect to have much 
higher infection rates, we did not find that to be the case in this study. From the findings of 
this study and also acknowledging its limitations, pacemaker and ICD reuse is feasible and 
safe, and is a reasonable option for those who cannot afford new devices, provided that 
proper selection and sterilization measures of re-used devices are followed. In the developing 
world where there are major resource constraints, this option should be explored for the 
benefit of those suffering from symptomatic bradyarrhythmias and life threatening 
tachyarrhythmias. 
 
We acknowledge several limitations of our study. First, this was a retrospective study with 
small sample size of cases with re-used pacemakers and implantable cardioverter 
defibrillators. Second, the follow up period of patients with re-used devices was relatively 
short with a median period of 15 months, with a significant number died within 3 months of 
device insertion. Finally, the patients who were selected for re-used pacemakers had 
significant co-morbidities which were associated with a shortned life-span.  These factors 
may limit the generalisability of the study, and call for appropriate prospective studies to 










Pacemaker and ICD reuse is feasible and safe in the short term (i.e., over months) provided 
that the devices for reuse are selected carefully and proper sterilization methods are followed. 
Re-used pacemakers and ICDs are a realistic option for patients with co-morbidities who live 
in developing countries where there is limited access to pacemaker and ICDs.  
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 ICD’s= Implantable Cardioverter-Defibrilators 
 n= Number 








Devices implanted 2003-2013 
(n= 1721) 
ICD’s n (%) – 134 (7.8) 
 
Pacemakers n (%) - 1587(92.2) 
 
First implants n (%) – 114 (85.1) 
Generator change n (%) – 20 (14.9) 
 
First implants n (%) - 1257 (79.2) 
 Generator change n (%) - 330 (20.8)  
 
Re-used ICD’s n (%) – 12 (9) 
 
Re-used pacemakers n (%) – 54 (3.4) 
 
Re-used devices n (%) – 66 (3.8) 
 Excluded n (%) – 3 (4.5) 
 Missing data 
Analysed (n=126) 
 
Pacemakers n (%) – 102 (81) 
 Re-used n (%) – 51 (50) 




ICD’s n (%) – 24 (19) 
 Re-used n (%) – 12 (50) 
 New n (%) – 12 (50) 
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 ICD’s= Implantable Cardioverter-Defibrillators
 n= Number
 (%)= Percentage
Did not follow up at 3 months n (%): 
 Cases: 25 (49)
 Died – 11 (44)
 Alive – 9 (36)
 Unknown status – 5 (20)
 Controls: 8 (15.7)
 Died -1 (12.5)
 Alive – 7 (87.5)
Seen at 3 months follow up n (%) 
 Cases: 12 (100)
 Controls: 12 (100)
Seen at 3 months follow up n (%): 
 Cases: 26 (51)
 Controls: 43 (84.3)
Did not follow up at 1 year n (%): 
 Controls: 1 (8.3)
 Alive – 1 (8.3)
Seen at 1 year follow up n (%): 
 Cases: 19 (37.3)
 Controls: 38 (74.5)
Seen at 1 year follow up n (%): 
 Cases: 12 (100)
 Controls: 11 (91.7)
Did not follow up at 1 year n (%): 
 Cases: 32 (62.7)
 Died – 15 (46.9)
 Alive – 9 (28.1)
 Unknown status – 8 (25)
 Controls: 13 (25.5)
 Died -3 (23.1)
 Alive – 7 (53.8)
 Unknown status- 3 (23.1)
Pacemakers n (%) – 102 (81) 
 Re-used n (%) – 51 (50)
 New n (%) – 51 (50)
ICD’s n (%) – 24 (19) 
 Re-used n (%) – 12 (50)
 New n (%) – 12 (50)
Analysed (n=126) 
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TABLE 1: Characteristics of patients who received pacemakers 
Characteristics Patients with re-used 
pacemakers (cases) 
Patients with new 
pacemakers (controls) 
P value 
Sample size n 51 51 
Age 74.33±17.26 72.86±16.13 0.658 













































Baseline function n (%) 
NYHA Functional Class 1 
NYHA Functional Class 2 



















Sick sinus syndrome n (%) 
0.138 
   Yes 9 (17.6) 4 (7.8) 
   No 42 (82.4) 47 (92.2) 
AV block n (%) 
0.22   Yes 38 (74.5) 43 (84.3) 
   No 13 (25.5)  8 (15.7) 
Others n (%) 
1.00    Yes 4 (7.8) 4 (7.8) 
   No 47 (92.2) 47 (92.2) 
First implantation n (%) 43 (84.3) 45 (88.2) 0.565 










Temporal lead n (%) 17 (33.3) 21 (41.2) 0.413 
















CVA= Cerebrovascular Accident; COPD= Chronic Obstructive Pulmonary Disease; NYHA= New York Heart 
Association; AV Block= Atrioventricular Block; n= Number; (%) = Percentage; 3/12= 3 months; YR= Year; Other= 
atrial fibrillation and heart failure. 
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TABLE 2: Pacemaker parameters 
Parameters Patients with re-
used pacemakers 
(cases)  




DDD n (%) 11 (21.6) 7 (13.7) 0.30 
VVI n (%) 39 (76.5) 42 (82.4) 0.463 
Others n (%) 1 (2) 2(3.95) 
Minimum pacing 
rate,bpm 
63.4±6.0 61.6±5.1 0.09 
Ventricular pacing 
% 
50 (98%) 49 (96.1) 0.558 
Battery voltage, V 2.78 (2.77-2.79) 













































Others= AAI, V= volts; mV= millivolts; ms= milliseconds; Ω= ohms; KΩ= kilohms; A=amperes; bpm= beats per minute; DDD= 






TABLE 3: Characteristics of patients who received implantable cardioverter-
defibrillators 
Characteristics Patients with re-used 
ICDs (cases) 
Patients with new ICDs 
(controls) 
P value  
Sample size n 12 12  
Age 49.83±17.34 50.58±17.27 0.916 

















































Baseline function n (%) 
NYHA Functional Class 1 
NYHA Functional Class 2 
















Ventricular Tachycardia n 
(%) 
9 (75) 10 (83.3) 0.615 
Others n (%) 3 (25) 2 (16.7) 0.615 
First implantation n (%) 12(100) 11(91.7) 0.307 
Generator change n (%) 0(0) 1 (8.3) 0.307 








































CVA= Cerebrovascular Accident; COPD= Chronic Obstructive Pulmonary Disease; NYHA= New York Heart Association; AV 
Block= Atrioventricular Block; n= Number; (%) = Percentage; 3/12= 3 months; YR= Year; Others= ventricular fibrillation and 






TABLE 4: Implantable cardioverter-defibrillator parameters 
Parameters Patients with re-
used ICDs (cases) 
Patients with new 
ICDs (controls) 
P value 
VVI n (%) 12 12 1.00 
Minimum pacing 
rate,bpm 
38.1±4.7 44.4±9.4 0.052 
Ventricular pacing 
% 
12 12 1.00 
Capture 
Amplitude, V 
Ventricular 0.618±0,28 0.708±0.32 0.481 
Sensitivity, mV 
Ventricular 12.925±6.93 16.118±6.17 0.258 
Output 
Amplitude, V 




784.75±304 648.83±147 0.177 
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